Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−860 KRW
−66.87 B KRW
4.43 B KRW
40.30 M
About GENEXINE, INC.
Sector
Industry
CEO
Seong-Joon Hong
Website
Headquarters
Seoul
Founded
1999
ISIN
KR7095700001
FIGI
BBG000NWBRZ3
Genexine, Inc. engages in research and development of novel immunotherapies for cancer and antibody therapies for rare diseases. Its pipeline of medicines is built upon its proprietary technologies, the hyFc and DNA vaccine platforms. The hyFc platform technology is used for development of long-acting protein drugs, maximizing the half-life of drugs in the human body through fusion with various drugs. The DNA vaccine platform inserts a genetic fragment involved in protein production into a vaccine, eliciting immune responses in the human body to fight viral infection and cancer cells. The company was founded by Young Chul Sung on June 8, 1999 and is headquartered in Seoul, South Korea.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 095700 is 5,320 KRW — it has decreased by −4.32% in the past 24 hours. Watch GENEXINE, INC. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange GENEXINE, INC. stocks are traded under the ticker 095700.
095700 stock has fallen by −3.97% compared to the previous week, the month change is a −8.43% fall, over the last year GENEXINE, INC. has showed a −43.16% decrease.
095700 reached its all-time high on Aug 27, 2020 with the price of 137,690 KRW, and its all-time low was 3,340 KRW and was reached on May 22, 2012. View more price dynamics on 095700 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
095700 stock is 5.26% volatile and has beta coefficient of 1.18. Track GENEXINE, INC. stock price on the chart and check out the list of the most volatile stocks — is GENEXINE, INC. there?
Today GENEXINE, INC. has the market capitalization of 241.95 B, it has increased by 5.24% over the last week.
Yes, you can track GENEXINE, INC. financials in yearly and quarterly reports right on TradingView.
GENEXINE, INC. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
095700 net income for the last quarter is −14.54 B KRW, while the quarter before that showed −12.09 B KRW of net income which accounts for −20.27% change. Track more GENEXINE, INC. financial stats to get the full picture.
No, 095700 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 93.00 employees. See our rating of the largest employees — is GENEXINE, INC. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENEXINE, INC. EBITDA is −27.47 B KRW, and current EBITDA margin is −833.53%. See more stats in GENEXINE, INC. financial statements.
Like other stocks, 095700 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENEXINE, INC. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENEXINE, INC. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENEXINE, INC. stock shows the sell signal. See more of GENEXINE, INC. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.